We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current TARS market cap is 2.03B. The company's latest EPS is USD -3.5549 and P/E is -14.80.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.87M | 13.08M | 27.61M | 40.81M | 48.12M |
| Operating Income | -40.94M | -44.45M | -37.68M | -33.3M | -25.16M |
| Net Income | -39.15M | -41.9M | -35.73M | -33.29M | -23.42M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 57.03M | 25.82M | 17.45M |
| Operating Income | -4.3M | -27M | -12.16M | -62.71M | -143.16M |
| Net Income | -4.67M | -26.81M | -13.83M | -62.09M | -135.89M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 268.33M | 265.49M | 349.28M | 376.84M | 376.3M |
| Total Liabilities | 54.67M | 68.5M | 74.07M | 124.6M | 138.82M |
| Total Equity | 213.66M | 196.99M | 275.21M | 252.25M | 237.48M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 58.32M | 171.97M | 178.91M | 227.86M | 265.49M |
| Total Liabilities | 919k | 5.99M | 12.18M | 34.96M | 68.5M |
| Total Equity | -6.01M | 165.98M | 166.73M | 192.9M | 196.99M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -78.16M | -117.49M | -37.79M | -52.19M | -60.85M |
| Investing | 122.75M | 140.6M | -102.22M | -142.75M | -139.62M |
| Financing | 110.42M | 130.18M | 108.77M | 151.09M | 151.73M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -3.67M | -21.14M | 3.75M | -49.03M | -117.49M |
| Investing | -175k | -456k | -586k | -144.63M | 140.6M |
| Financing | 59.45M | 131.77M | 21k | 93.99M | 130.18M |
| Market Cap | 2.03B |
| Price to Earnings Ratio | -14.80 |
| Price to Sales Ratio | 115.25 |
| Price to Cash Ratio | 8.94 |
| Price to Book Ratio | 10.21 |
| Dividend Yield | - |
| Shares Outstanding | 38.23M |
| Average Volume (1 week) | 1.05M |
| Average Volume (1 Month) | 667.67k |
| 52 Week Change | 158.79% |
| 52 Week High | 57.14 |
| 52 Week Low | 20.0818 |
| Spread (Intraday) | 7.28 (12.66%) |
| Company Name | Tarsus Pharmaceuticals Inc |
| Address |
3500 s dupont hwy dover, delaware 19901 |
| Website | https://www.tarsusrx.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
